Cabenuva

ViiV Healthcare Company🇺🇸 United States

FDA Page

Effective Date: Dec 13, 2023
Approval ID: 1698baf3-f895-4c42-a1b1-e9ee3f20da36
Products: 2 registered
Version: 11

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA.CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular useInitial U.S. Approval: 2021

Quick Stats

Total Products2

Labelers2

Label Sections20

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.